TickerFacts.

Kyverna Therapeutics, Inc. (KYTX): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$168.03M
Year ended 2025-12-31
-$157.36M
Trailing 12 months to 2026-06-30
2023-12-31: -$60.70M2024-12-31: -$140.47M2025-12-31: -$168.03M-$168.03M
2023-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$168.03Mn/m2026-03-26, From 2025-01-01
2024-12-31-$140.47Mn/m2026-03-26, From 2024-01-01
2023-12-31-$60.70Mn/a2025-03-27, From 2023-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Kyverna Therapeutics, Inc. (KYTX)2025-12-31-$168.03Mn/m
Alector, Inc. (ALEC)2025-12-31-$150.29Mn/m
X4 Pharmaceuticals, Inc (XFOR)2025-12-31-$85.61Mn/m
LENZ Therapeutics, Inc. (LENZ)2025-12-31-$90.85Mn/m
Fate Therapeutics Inc (FATE)2025-12-31-$134.80Mn/m
Lexeo Therapeutics, Inc. (LXEO)2025-12-31-$108.99Mn/m
Tectonic Therapeutic, Inc. (TECX)2025-12-31-$82.66Mn/m
Replimune Group, Inc. (REPL)2026-03-31-$316.59Mn/m
Coherus Oncology, Inc. (CHRS)2025-12-31-$177.21Mn/m

Compare KYTX, ALEC, XFOR, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗